Exact, GE Healthcare to develop ACT ultrasound probe

2020 01 29 18 12 5932 Ge Rsna 2019 400

Exact Therapeutics and GE Healthcare are developing an ultrasound probe that will be used to test acoustic cluster therapy (ACT) for multiple diseases in upcoming studies.

ACT is a proprietary formula that consists of microbubbles and microdroplets that are activated via ultrasound to increase the targeted delivery of a co-administered therapeutic agent. Preclinical data have shown that it enhances treatment for pancreatic, breast, colon, and prostate cancer, as well as managing blood-brain barrier opening.

The therapy is being evaluated in patients with metastatic colorectal and pancreatic cancer in a phase I trial at the Royal Marsden Hospital in London.

Page 1 of 549
Next Page